In the world of metabolic research, we are witnessing a rapid evolution. First came Semaglutide, the GLP-1 pioneer. Then came Tirzepatide, the dual-agonist powerhouse. Now, all eyes are on Retatrutide,…
For years, Semaglutide (a GLP-1 receptor agonist) redefined the treatment of obesity and Type 2 Diabetes. But then came Tirzepatide—a groundbreaking "dual agonist" that pushed the boundaries even further. For…
The landscape of metabolic research is shifting rapidly. For years, Semaglutide has been the undisputed leader in peptide-based weight management. However, a new contender known as Retatrutide—nicknamed the "Triple G"—is…